ReviewFrontiers in neurology
Tissue clock-guided prediction and intervention of futile recanalization: towards precision therapy in mechanical thrombectomy.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Recanalization: A Mechanistic and Procedural Framework for Adjunct Pharmacologic Therapy During Mechanical Thrombectomy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanical thrombectomy (MT) is the standard of care for acute ischemic stroke caused by large vessel occlusion (LVO). Yet despite achieving high rates of angiographic reperfusion, nearly half of treated patients do not regain functional independence-a phenomenon termed futile recanalization (FR). This persistent gap between vessel patency and clinical recovery exposes the fundamental limitations of traditional time-based treatment paradigms, which assume a uniform rate of ischemic progression across individuals. The pathophysiology of FR is multifactorial, involving microvascular no-reflow, early arterial reocclusion, collateral circulation failure, and reperfusion-mediated injury. These mechanisms interact in a complex, temporally evolving cascade that cannot be captured by a single imaging or clinical metric. The emerging "tissue clock" framework reframes patient selection from elapsed time to individualized tissue viability, drawing on advanced imaging biomarkers including diffusion-FLAIR mismatch, net water uptake quantification, infarct core-penumbra dynamics, and collateral hemodynamic assessment. The DAWN and DEFUSE 3 trials provided landmark evidence that imaging-guided selection enables safe and effective thrombectomy well beyond conventional time windows, validating the clinical relevance of tissue-based decision-making. In parallel, predictive modeling has evolved from traditional clinical scoring systems toward machine learning-based and multimodal approaches that integrate clinical, imaging, and biological variables for individualized risk stratification. The tissue clock paradigm thus marks a conceptual shift from population-level time thresholds to individualized pathophysiological assessment. By integrating imaging biomarkers, circulating biological indicators, and computational prediction models, clinicians may achieve more accurate outcome prediction and deploy multi-target interventions to mitigate FR. Realizing this vision will require standardized tissue clock quantification protocols, prospective validation of artificial intelligence models across diverse populations, and translational evaluation of combination therapies-ultimately aligning successful recanalization with durable functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.